Regeneron drug said to cut muscle loss when combined with Novo's semaglutide

[Doctor doing research in lab during COVID-19] Morsa Images * An experimental weight-loss drug being developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) used in combination with Novo Nordisk's (NVO [https://seekingalpha.com/symbol/NVO]) semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone ​in a study of patients with obesity, according to data being presented at a medical meeting, as per Reuters. * The Regeneron drug, trevogrumab, belongs to a different class of medicines that inhibits the protein myostatin, which is linked to loss of muscle mass.